Literature - Cancer Treatment | Theranostics Australia


Enter keywords within the Search Bar below to segment, categorise and narrow publication results.

Example Keywords: NET, Prostate, Metastatic, Lutetium-177, Rituximab, PSMA, Octreotate etc.

Alternatively, use the Field Ordering Arrows in the table header to order publications by Title, Author, Journal and Date.


177Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical ResultsBaum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling CJournal of Nuclear Medicine2018 May
68Ga-PSMA PET/CT Revealing Unusual Inguinal Canal and Distant Nodal Metastasis in a Case of Castration-Resistant Prostate Cancer.Vadi SK, Kumar R, Mittal BR, Singh H, Singh SK.Journal of Clinical Nuclear Medicine2018 April
Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer.Chaussé G, Abikhzer G, Probst S.Journal of Clinical Nuclear Medicine2018 April
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms.Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Hörsch D.Oncotarget2018 February
Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.European Journal of Nuclear Medicine and Molecular Imaging2018 February
68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning Calais J, Czernin J, Cao M, Kishan A, Hegde J et al.Journal of Nuclear Medicine2018 February
Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor-control.Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A.Journal of Nuclear Medicine2018 January
Current status of theranostics in prostate cancer.Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C.European Journal of Nuclear Medicine and Molecular Imaging2017 December
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T.European Journal of Nuclear Medicine and Molecular Imaging2017 December
Prostate-specific membrane antigen theranostics: therapy with lutetium-177.Ferdinandus J, Violet J, Sandhu S, Hofman MSCurrent Opinion in Urology2017 December
177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancerBoegemann M, Schrader AJ, Rahbar K.Der Urologe2017 November
Why targeting PSMA is a game changer in the management of prostate cancer - a Urologist's point of view. Donin NM, Reiter R.Journal of Nuclear Medicine2017 October
Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.Calopedos RJS, Chalasani V, Asher R1, Emmett L, Woo HH.Prostate Cancer & Prostatic Diseases2017 August
Repeated Lu-177-PSMA-617 radioligand therapy using treatment activities up to 9.3 GBq.Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, Haberkorn U, Kratochwil C.Journal of Nuclear Medicine2017 August
177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer.von Eyben FE, Kiljunen T, Joensuu T, Kairemo K, Uprimny C, Virgolini I.Oncotarget2017 August
177Lu-PSMA Radioligand Therapy for Prostate CancerFendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M.Journal of Nuclear Medicine2017 August
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry.Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, Aygün A, Karayel E, Pehlivanoğlu H, Alan Selçuk N.Molecular Imaging and Radionuclide Therapy2017 June
The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter studyROACH PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen Q, Thompson B, Cusick T, McCarthy M, Tang C, Ho B, Stricker P, Scott A.Journal of Nuclear Medicine2017 June
177Lu-PSMA radioligand therapy for prostate cancerFendler WP, Rahbar W, Herrmann K, Kratochwil C and Eiber M.Journal of Nuclear Medicine2017 July
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.Roll W, Bode A, Weckesser M, Bögemann M, Rahbar K.Journal of Clinical Nuclear Medicine2017 February
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, Wester HJ, Baum RP.Journal of Nuclear Medicine2016 October
Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions.Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendlder WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M.Journal of Nuclear Medicine2016 September
Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience.Hope TA, Truillet CC, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ.Journal of Nuclear Medicine2016 September
68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept.Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner F, Kürpig S, Strunk H4, Essler M.Journal of Nuclear Medicine2016 September
Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617.Ferdinandus J, Eppard E, Gärtner F, Kürpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H.Journal of Nuclear Medicine2016 September
Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL.Seminars in Nuclear Medicine2016 September
Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, Bögemann M.Journal of Clinical Nuclear Medicine2016 July
Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol.Demir M, Abuqbeitah M, Uslu-Beşli L, Yıldırım Ö, Yeyin N, Çavdar İ, Vatankulu B, Gündüz H, Kabasakal L.Journal of Radiological Protection2016 June
Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.Das T, Guleria M, Parab A, Kale C, Shah H, Sarma HD, Lele VR, Banerjee S.Journal of Nuclear Medicine and Biology2016 May
Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis.Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar HJournal of Nuclear Medicine2016 April
PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617.Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn UJournal of Nuclear Medicine2016 March
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M.Oncotarget2016 March
Systemic radioligand therapy with 177Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancerHeck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester H, Gschwend JE, Schwaiger M, Tauber R, Eiber MThe Journal of Urology2016 March
Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyBaum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJournal of Nuclear Medicine2016 January
Use of yttrium-90 hydroxyapatite radiosynovectomy as a primary modality of treatment in diffuse pigmented villonodular synovitis of the knee joint: A first case reportKamaleshwaran KK, Rajan D, Krishnan B, Gounder TS, Chakraborty S, Kalarickal R, Mohanan V, Shinto AS.Indian Journal of Nuclear Medicine2015 March
Higher Tumour Uptake and Residence Time Enhance the Therapeutic Index of the Radiolabeled Somatostatin Antagonists over the Agonists: The Influence of the Peptide MassOctreoPharm Sciences GmbHOral Presentation Abstract2014 October
[68Ga]-OPS202 targeting somatostatin receptors: In vivo biodistribution and dosimetry in a pig modelOctreoPharm Sciences GmbHPoster Presentation Abstract2014 October
Radiosynovectomy in pigmented villonodular synovitis.Kat S, Kutz R, Elbracht T, Weseloh G, Kuwert T.Nuklearmedizin (Nuclear Medicine)November 2000

Reference: PubMed